Scribe Therapeutics listed in late July as a CRISPR cardiometabolic company that has already put a PCSK9 epigenetic silencer into humans. The equity now trades well above the offering print even though no patient-level efficacy exists. That gap between listing celebration and clinical proof is the entire investment debate. The company is selling a durable, non-permanent alternative to both chronic cholesterol drugs and permanent genome editors. The market is treating that story as if the primate package already translates.
The July financing and a concurrent Sanofi private placement left a cash pile large enough for management to guide operations into the first half of 2029. Two California Institute for Regenerative Medicine awards also cover the lipoprotein(a) and triglyceride follow-ons toward clinic entry. Collaboration revenue, however, has already faded as reimbursable work with Prevail Therapeutics slowed. The pre-listing quarter still carried a going-concern warning that the completed offering later lifted. Capital is no longer the binding constraint. Translation of a multi-year primate LDL-C effect into people is.
The June quarter is a pre-listing print. Cash sat at $43 million. The quarterly loss narrowed while research spending fell even as the Phase 1 study started. Mid-year cash plus stated net proceeds near $141 million is the funded starting line. The only observation that can reprice the platform on evidence rather than narrative is the first single-ascending-dose readout. Whether that package, guided for the first half of 2027, shows meaningful LDL-C lowering without a safety surprise decides if today's premium survives.